Health Care • Medicinal Chemicals and Botanical Products
$8.33 ▼ -0.19
(-2.23%)
MKT CAP: $16.1M • VOL: 34.6K
52W L $4 52W H $12
MTEX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $108.0M | $117.9M | $132.0M |
| YoY Revenue Growth % | -8.3% | -10.7% | — |
| Gross Profit | $81.0M | $91.5M | — |
| Gross Margin % | 74.9% | 77.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$426.0K | $1.4M | -$964.0K |
| Operating Margin % | -0.4% | 1.2% | -0.7% |
| Net Income (GAAP) | -$15.2M | $2.5M | -$2.2M |
| EBITDA (Normalized) | $656.4K | $1.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.0M | $2.3M | -$2.4M |
| Capital Expenditures (CapEx) | $1.4M | $297.0K | — |
| Free Cash Flow (FCF) | -$4.3M | $2.0M | -$2.4M |
| FCF Margin % | -4.0% | 1.7% | -1.8% |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $6.2M | $11.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$5.2M | $8.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MTEX.